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Abstract
Objective: Increasing plasma glucose levels are associated with increasing risk of vascular disease. We tested the hypothesis
that there is a glycaemia-mediated impairment of reverse cholesterol transport (RCT). We studied the influence of plasma
glucose on expression and function of a key mediator in RCT, the ATP binding cassette transporter-A1 (ABCA1) and
expression of its regulators, liver X receptor-a (LXRa) and peroxisome proliferator-activated receptor–c (PPARc).
Methods and Results: Leukocyte ABCA1, LXRa and PPARc expression was measured by polymerase chain reaction in 63
men with varying degrees of glucose homeostasis. ABCA1 protein concentrations were measured in leukocytes. In a sub-
group of 25 men, ABCA1 function was quantified as apolipoprotein-A1-mediated cholesterol efflux from 2–3 week cultured
skin fibroblasts. Leukocyte ABCA1 expression correlated negatively with circulating HbA1c and glucose (rho=20.41,
p,0.001; rho=20.34, p=0.006 respectively) and was reduced in Type 2 diabetes (T2DM) (p=0.03). Leukocyte ABCA1
protein was lower in T2DM (p=0.03) and positively associated with plasma HDL cholesterol (HDL-C) (rho=0.34, p=0.02).
Apolipoprotein-A1-mediated cholesterol efflux correlated negatively with fasting glucose (rho=20.50, p=0.01) and
positively with HDL-C (rho=0.41, p=0.02). It was reduced in T2DM compared with controls (p=0.04). These relationships
were independent of LXRa and PPARc expression.
Conclusions: ABCA1 expression and protein concentrations in leukocytes, as well as function in cultured skin fibroblasts, are
reduced in T2DM. ABCA1 protein concentration and function are associated with HDL-C levels. These findings indicate a
glycaemia- related, persistent disruption of a key component of RCT.
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Introduction
People with hyperglycaemia are at increased risk of coronary
heart disease (CHD). The risk is high in type 2 diabetes (T2DM)
(2–4 fold elevation) [1] and applies even to those with lesser
degrees of glucose elevation (impaired glucose regulation). Even in
the general population, there is a positive relationship between
glucose (or HbA1c) levels and CHD rates.[2] Several underlying
mechanisms have been proposed, including protein glycation and
free radical damage.[3] Both diabetes and impaired glucose regu-
lation are accompanied by dyslipidaemia, a major feature of which
is low levels of circulating high density lipoprotein cholesterol
(HDL-C). Impaired reverse cholesterol transport (RCT) has
therefore been implicated.[4]
RCT is the process by which excess cholesterol is removed
from the body. It begins in peripheral tissues when lipid-poor
apolipoprotein A-I (apo-A1) induces cholesterol and phospho-
lipid mobilisation from intracellular storage sites to the plasma
membrane.[5] The membrane-associated ATP binding cassette
transporter-A1 (ABCA1) is integral to the subsequent transmem-
brane lipid transfer to form nascent HDL.[6] Later cholesterol
efflux to HDL is mediated by the related transporter, ATP binding
cassette transporter-G1 (ABCG1) with some evidence of syner-
gism.[7] Defects in ABCA1 impair apo-A1-mediated lipid efflux
from cells and ABCA1 knockout mice develop early atherosclero-
sis.[8,9] Functional ABCA1 mutations in both Tangier disease and
familial HDL deficiency lead to very low levels of circulating HDL,
almost all of which is lipid-poor, as newly synthesised apo-A1 fails
to acquire cholesterol and phospholipids.[10]
ABCA1 expression in several tissues is up-regulated by oxysterol
interaction with the liver X receptor-a (LXRa). Stimulation of
LXRa transcription by peroxisome proliferator-activated receptor-
c (PPARc) upregulates ABCA1 expression and increases apo-A1-
mediated cholesterol efflux from macrophages.[11]
ABCA1 expression is decreased in the liver and peritoneal
macrophages of diabetic compared to control mice and protein
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diabetes.[12,13] In human studies, fibroblast ABCAI function has
been shown to be impaired by advanced glycation end products
[14] and we have previously observed an inverse relationship
between ABCA1 expression in peripheral leucocytes and fasting
glucose in healthy young and middle-aged men.[15] These
findings suggested a potential mechanism for the hyperglycae-
mia-induced increased risk of early vascular disease. In the present
study, we explore relationships between glycaemia, expression of
ABCA1 and ABCG1, ABCA1 protein concentrations and ABCA1
function in people with varying degrees of hyperglycaemia, and
whether these relationships are influenced by LXRa or PPARc
expression.
Methods
Participants
Sixty three men aged over 18 years were recruited from regional
metabolic clinics and primary care, with the assistance of the UK
Diabetes Research Network. Participants included 18 with T2DM
and 18 with impaired glucose regulation by World Health Orga-
nization criteria. The patients with T2DM were treated with diet
alone and had not taken hypoglycaemic or lipid-lowering medica-
tion. Subjects taking systemic corticosteroids or medications with
marked effects on insulin secretion were excluded. Patients were
free of microvascular and macrovascular complications. 27
healthy, aged matched normoglycaemic controls were also studied
following local advertisement.
Ethics statement
Written consent was obtained and ethical approval for the study
was from the Hammersmith, Queen Charlotte’s and Chelsea
Research Ethics Committee (REC Reference 05/Q0406/33). The
study protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki.
Procedures
After an overnight fast, a clinical and routine biochemical
assessment was conducted. The control subjects and those without
known diabetes underwent a 75g Oral Glucose Tolerance Test
(OGTT) and were classified using the American Diabetes Asso-
ciation criteria (2003).[16] Fasting blood samples only were taken
from patients with known T2DM. 25 participants, selected ran-
domly, consented to undergo more detailed investigation which
involved a 4 mm punch skin biopsy sample from the forearm under
sterile conditions to enable functional analyses in skin fibroblasts.
Laboratory measurements
Fasting glucose, creatinine and liver enzymes were measured
using standard laboratory techniques. HbA1c (DCCT aligned) was
measured by cation-exchange high performance liquid chroma-
tography using a Tosoh Automated glycohaemoglobin analyser
G7 (Tosoh Bioscience Inc., Tokyo, Japan). Cholesterol, lipopro-
tein and triglyceride measurements were performed using an
Olympus AU 2700 autoanalyser (Olympus Life & Material
Science, Ireland). LDL-cholesterol was calculated using the
Friedewald formula. Plasma non-esterifed fatty acid (NEFA)
concentrations were measured by an in vitro colorimetric method
(Wako Chemicals, Neuss, Germany) using a Cobas Mira analyzer
(Hoffman-LaRoche and company, Basel, Switzerland).
Leukocyte isolation and gene expression
Peripheral leukocytes were isolated from 12 ml blood in subjects
and frozen at 280uC after erythrocyte lysis (Qiagen, Crawley,
UK). Total RNA extraction was performed using Qiashredder
and RNeasy (Qiagen) according to manufacturer’s protocol.
Reverse transcription and multiplex quantitative PCR were
performed using a high capacity cDNA reverse transcription kit
and Taqman universal mastermix reagents (Applied Biosciences,
Warrington, UK). Primer and probe sets were exon overlapping
(Applied Biosystems). A Rotorgene thermal cycler (Corbett Life
Science, Cambridge, UK) was used to measure gene expression.
cDNA (30 ng) was amplified in a total volume of 10 mL. b-Actin
was used as the housekeeper gene. All experiments were per-
formed in duplicate. This technique was validated in our earlier
study.[15] ABCA1 expression results were further validated in 25
subjects using an additional housekeeper, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). As results with GAPDH were
very similar to those with b-Actin, only b-Actin derived data are
described. Target gene quantity was calculated from a standard
curve. Gene expression data from multiple experiments were
compared to a calibrator sample and normalised to the house
keeper gene.
Leukocyte protein expression
Total cell lysates were prepared by incubating the leukocyte cell
pellets (n=50) with 1 ml ice-cold lysis buffer (50 mM mannitol,
2 mM EDTA, 50 mM, pH 7.6) containing complete protease
inhibitor (Roche, Germany) and 0.1% w/v Triton X-100 for 60
minutes on ice. This was followed by five homogenization cycles
(20 s each and 10 minutes resting time on ice after each homo-
genization step) in a Fastprep homogenizer. The leukocyte homo-
genates were centrifuged at 15,000 g for 15 minutes at 4uC and
the supernatants containing clear cell lysates were collected.
Protein concentrations were determined by a bicinchoninic acid
assay.[17] The clear leukocyte cell lysates were stored at 280uC
until ABCA1 protein measurement was performed. Frozen leuko-
cyte lysates were thawed and ABCA1 protein concentration was
measured using an ELISA method as previously described.[18]
Briefly, either 50 ml ABCA1 peptide (ab14148, Abcam, UK)
calibrators (range 8–1000 ng) or 50 ml of unknown leukocyte
lysates were incubated in a ABCA1 peptide pre-coated and BSA
blocked micro titre plate along with 100 ml( 2mg/l diluted in
PBST) anti-ABCA1 rabbit antibody (ab7360, Abcam, UK). The
incubation was carried out for 5 hours at room temperature while
shaking on an ELISA plate shaker. The plate was washed with
PBST and further processed by using biotin labelled anti-rabbit
IgG goat antibody, streptavidin-HRP conjugate and tetramethyl-
benzidine enzyme substrate system. The enzymatic reaction was
stopped by addition of sulphuric acid and absorbance measured at
450 nm on an ELISA plate reader (Sunrise, Tecan, Austria).
ABCA1 protein concentrations of unknown samples were calcu-
lated from a calibration curve and results were expressed as
ABCA1 protein ng/mg total protein.
Fibroblast cell culture and cholesterol efflux
measurement
Primary fibroblast cell lines were obtained from human dermal
biopsy following enzymatic digestion in the sub-group of 25
subjects (9 controls, 6 with impaired regulation and 10 T2DM)
who underwent a skin biopsy. Primary cells were cultured with
DMEM (Invitrogen Ltd, Paisley, UK) which contained 25 mmol/l
glucose, supplemented with 10% fetal bovine serum and 1%
antimicrobial solution (Sigma-Aldrich Co, Poole, UK). The
medium was changed twice weekly until cells were 80-100%
confluent. After culture for 2–3 weeks, cells from passage 4 to 7
were used for cholesterol efflux measurements. Fibroblasts were
plated in wells until 60–80% confluence. Cholesterol loading and
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methodology using apo-A1.[19] In brief, cells were loaded with
0.5 mCi/ml 1,2-
3[H]-cholesterol (Perkin Elmer, Boston, MA) for
24 hours in the presence of 30 mg/ml unlabelled cholesterol
(Sigma-Aldrich Co.) to induce ABCA1. Cells were then washed
with PBS/BSA 0.2% (v/v) and efflux was commenced using
10 mg/ml apo-A1 (Sigma-Aldrich Co.). After 20 hrs the medium
was collected, centrifuged and radioactivity was measured using
liquid scintillation counting (Beckman LS6000 Coulter UK Ltd,
High Wycombe, UK). Cellular cholesterol was extracted using
hexane/propanol (3:2 v/v) and counted. Percentage cholesterol
efflux was calculated by dividing the radioactive counts in the
efflux medium by the sum of the counts in the media and cell
extract. Experiments were performed in triplicate with a mean CV
of 12%. Apo-A1-mediated lipid export was derived by subtraction
of non-specific efflux (measured in control wells without apo-A1).
Statistical analysis
Variation between the groups was compared by ANOVA, or
Kruskal-Wallis test depending on variable distribution. Likewise, a
t-test or Mann-Whitney test was used to compare individual
groups Smoking status was analysed using a Chi squared test.
Relationships between variables were assessed by Spearman correla-
tion. Multiple linear regression was used to assess independence of
relationships after log- transformation, where appropriate, to
normalise distributions. A two sided p value ,0.05 was considered
significant. Sigmastat version 3.5 (Systat Software, Inc.) and Prism
version 4 (Graphpad Software, Inc.) were used for analyses and
graphical illustration, respectively.
Results
As expected, patients with diabetes were heavier compared to
controls and had a greater waist circumference (Table1). HDL-C
was significantly lower in patients with diabetes, compared with
controls, but other lipid parameters were not significantly different
across subject groups. Standard laboratory renal, liver and thyroid
function tests were normal in all subjects. HbA1c and fasting
glucose have been used as the indices of glycaemia as they were
measured in all subjects and they correlated strongly with each
other (rho=0.77, p,0.0001).
ABCA1 gene expression and protein concentrations in
peripheral blood leukocytes
Leukocyte ABCA1 expression was significantly lower in patients
with T2DM compared with controls (p=0.03; Figure 1A). In the
combined groups, ABCA1 expression fell with increasing HbA1c
(rho=20.41, p,0.001; Figure 2A) and with increasing fasting
glucose levels (rho=20.34, p=0.006; Figure 2B).
There was no significant relationship between leukocyte ABCA1
expression and age, body mass index or waist circumference.
Leukocyte ABCA1 protein concentration was lower in patients
with T2DM compared with controls (p=0.03; Figure 1B)
although the relationship with fasting glucose was not significant
statistically (rho=20.25, p=0.08). No significant relationship was
observed between plasma NEFA levels and ABCA1 expression
(p=0.40).
Relationship of ABCG1 expression with glycaemia and
ABCA1 expression
Leukocyte ABCA1 and ABCG1 expression were positively related
(rho=0.40, p=0.005, Figure S1). Leukocyte ABCG1 expression in
patients with T2DM was not significantly reduced (p=0.08) and
there were no differences between other groups. There was a
borderline negative relationship between leukocyte ABCG1
expression and HbA1c (rho=20.29, p=0.05) Figure S1, but
not fasting glucose (p=0.35). Analysis of ABCA1 expression and
glycaemia (mean glucose or HbA1c) using a linear model,
demonstrated that only ABCA1 expression remained a significant
predictor of ABCG1 expression.
Apolipoprotein-A1 mediated cholesterol efflux in skin
fibroblasts and glycaemia
Apo-A1-mediated cholesterol efflux from fibroblasts was
reduced by 36% in diabetes (p=0.04; Figure 3A). After adjusting
Table 1. Baseline participant demographic data.
Variable Controls (n=27) IGH (n=18) DM (n=18) ANOVA (p)
Age, yrs 52616 58685 7 611 0.40
BMI, kg/m
2 24.362.2 27.364.1 27.963.2* ,0.001
Waist circumference, cm 91 (85–96) 96 (87–105) 101 (94–105) * 0.003
Alcohol consumption,units 20 (4–24) 8 (2–18) 12 (2–20) 0.15
Smokers, % 3 (10) 6 (33) 4 (22) 0.192
Systolic BP, mmHg 132613 138617 131614 0.30
Diastolic BP, mmHg 81610 83611 8266 0.77
Fasting Glucose, mmol/l 5.10 (4.70–5.40) 5.56 (4.95–5.95) 6.8 (6.3–8.8) { ,0.001
HbA1c, % 5.560.4 5.960.5 7.361.5{ ,0.001
2 hr Glucose, mmol/l 4.961.3 7.362.2* - ,0.001
Total Cholesterol, mmol/l 5.3860.89 5.1461.06 5.0361.10 0.49
HDL-C, mmol/l 1.5360.29 1.3260.38 1.2360.26* 0.005
LDL-C, mmol/l 3.2960.65 3.2660.71 3.1160.89 0.72
Triglycerides, mmol/l 1.17 (0.74–1.59) 0.97 (0.77–1.38) 1.37 (0.94–2.11) 0.18
Normally distributed variables are expressed as mean and standard deviation. Skewed data are represented by median (interquartile range).
Abbreviations: IGH=impaired glucose regulation; DM=type 2 diabetes; ANOVA or equivalent analysis of variance; *p,0.05 relative to controls, {p,0.05 relative to
control and IGH subjects.
doi:10.1371/journal.pone.0022142.t001
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patients with diabetes compared to healthy men (4.5% versus
11.2%, p=0.008). Efflux fell with increasing fasting plasma
glucose (rho=20.50, p=0.01; Figure 3B). The inverse relation-
ship with HbA1c was not statistically significant (rho=20.30,
p=0.07). There was no significant relationship between apo-A1-
mediated cholesterol efflux and age nor with body weight. Apo-
A1-mediated cholesterol efflux from fibroblasts fell with increasing
waist circumference (r=20.53, p,0.01) but bivariate analysis
demonstrated this relationship to be dependent on fasting plasma
glucose.
Relationship of ABCA1 with LXRa and PPARc
There was no significant relationship between fasting plasma
glucose nor HbA1c levels and either leukocyte PPARc (versus
HbA1c p=0.15, Figure S3) or LXRa (versus HbA1c p=0.87,
Figure S2) expression. Leukocyte LXRa expression was positively
related to leukocyte ABCA1 (r=0.40, p=0.002), Figure S2, as well
as ABCG1 (rho=0.67, p,0.001) expression, but there were no
such relationship between leukocyte ABCA1 and PPARc expression
(Figure S3). Using bivariate linear regression, fasting plasma
glucose concentrations and leukocyte LXRa expression both
remained independent predictors of leukocyte ABCA1 gene
expression (p=0.005 and p=0.001 respectively). Neither LXRa
expression nor glycaemia were significant independent contribu-
tors to ABCG1 expression.
Relationship of ABCA1 to plasma HDL cholesterol
Leukocyte ABCA1 and ABCG1 expression did not significantly
associate with plasma HDL-C concentrations. Leukocyte ABCA1
protein concentrations correlated positively and independently
with circulating plasma HDL-C levels (rho=0.34, p=0.02;
Figure 4A). Cholesterol efflux related positively to plasma HDL-
C concentrations (rho=0.41, p=0.02; Figure 4B).
Figure 1. ABCA1 gene expression and protein concentration in blood leukocytes is reduced in type 2 diabetes. A. Leukocyte ABCA1
gene expression, normalised to housekeeper gene (mean and standard error) according to subject glycaemic status in 63 participants. Con=Controls
(n=27), IGH=Impaired glucose regulation (n=18), DM=type 2 diabetes (n=18). Con vs. DM; p=0.03, Con vs. IGH; p=0.27, IGH vs. DM p=0.33
(* p,0.05). B. Leukocyte ABCA1 protein concentration (ng/mg protein) expressed as mean and standard error is illustrated according to subject
glycaemic status in 50 participants. Con=Controls (n=17), IGH =Impaired glucose regulation (n=17), DM=type 2 diabetes (n=16) Con vs DM;
p=0.03, Con vs IGH; p=1; IGH vs DM p=0.06 (* p,0.05).
doi:10.1371/journal.pone.0022142.g001
Figure 2. Leukocyte ABCA1 gene expression is reduced with increasing glycaemia. A. Relationship of leukocyte ABCA1 expression
(normalised to housekeeper gene) to glycated haemoglobin (HbA1c) in 63 participants (27 control, 18 impaired glucose homeostasis and 18 type 2
diabetes) rho=20.41, p,0.001. B. Relationship of leukocyte ABCA1 expression (normalised to housekeeper gene) to fasting plasma glucose in 63
participants (27 control, 18 impaired glucose homeostasis and 18 type 2 diabetes) rho=20.34, p=0.006.
doi:10.1371/journal.pone.0022142.g002
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We have demonstrated that ABCA1 gene expression, protein
concentrations and transporter function are reduced in drug naive
men with T2DM. Gene expression and protein concentrations
were reduced in blood leukocytes, and cellular cholesterol removal
to Apo-A1 (which exclusively involves ABCA1) was reduced in
skin fibroblasts. These relationships were independent of variation
in LXRa or PPARc expression. These observations suggest novel
mechanisms whereby hyperglycaemia could adversely influence
cellular cholesterol metabolism. Such mechanisms could contrib-
ute to the well-established association between elevated glucose
levels and risk of vascular disease.
ABCA1 is highly expressed in macrophages. Ideally, ABCA1
expression and protein content should be studied in arterial wall
macrophages, but this was not possible for ethical reasons.
Leukocyte ABCA1 RNA levels in humans reflect ABCA1 expression
in circulating monocytes and can be used as a marker for this.[20]
It should be noted that gene expression increases 4-fold in
monocytes during differentiation into macrophages.[21] Periph-
eral blood leukocytes have the advantage of being readily obtained
from large numbers of subjects and leukocyte ABCA1 has proven a
useful surrogate in other clinical situations where the variations in
ABCA1 expression have been observed in man.[22]
Leukocyte ABCA1 has not been previously considered to
influence plasma HDL or RCT directly.[20,23] Recent data,
however, have suggested that cells other than macrophages
influence tissue cholesterol removal (eg adipocytes).[24] Leuko-
cyte ABCA1 is known to protect against atherosclerosis in
animals [25], but our observations cannot distinguish between
possible direct and indirect effects of leukocyte ABCA1 on lipid
transport.
Figure 3. Cholesterol efflux in skin fibroblasts is reduced in type 2 diabetes and with increasing blood glucose concentration. A.
Cholesterol efflux to Apo-A1 according to glycaemic status in a subgroup of 25 men (Mean and Standard error). 0.5 mCi/ml 1,2-
3[H]-cholesterol was
loaded onto cells for 24 hours in the presence of 30 mg/ml unlabelled cholesterol. After equilibration, apo-A1 (10 mg/ml) was added to initiate efflux and
incubated for 20 hours. Control wells were incubated with culture media alone and apo-A1 mediated efflux was calculated by subtracting background
efflux from efflux mediated by apo-A1. Con=Control (n=9) IGH=Impaired glucose regulation (n=6), DM=type 2 diabetes (n=10). Con versus DM;
p=0.04, Con vs. IGH;p=0.39(*p,0.05). B. Relationship between fasting glucose andfibroblastapo-AI-mediated cholesterol efflux. rho=20.50, p=0.01.
doi:10.1371/journal.pone.0022142.g003
Figure 4. Positive relationship of human ABCA1 measurements with plasma HDL-C concentration. A. ABCA1 protein concentration in
leukocytes positively associates with plasma HDL-C concentration. n=50, rho=0.34, p=0.02. B. Cholesterol efflux to apo-A1 positively relates with
plasma HDL-C concentrations. Relationship between ABCA1-mediated cholesterol efflux in fibroblasts (mean of triplicate experiments) and plasma
HDL-C concentration. n=25, rho=0.41, p=0.02.
doi:10.1371/journal.pone.0022142.g004
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with T2DM and was directly related to the level of glycaemia.
Most of the decline in gene expression occurred up to an HbA1c
level of 7.5%, with little further fall above this value. Our ABCA1
expression data are compatible with and extend our previous
findings in healthy men.[15] We further demonstrate concordant
changes in leukocyte ABCA1 expression and protein concentra-
tions in patients with T2DM. Our leukocyte expression results
appear to contrast with the findings reported by Hoang and
colleagues who did not find a difference in leukocyte ABCA1
expression between patients with diabetes and controls.[22] This
previous study was conducted in a smaller cohort with one third of
patients receiving hypoglycaemic medications. ABCA1 function
was assessed on the basis of the ability of the subject’s plasma to
induce cholesterol efflux from human macrophages cell lines. [22]
There were baseline differences in lipid parameters which may
have had an effect on the capacity of plasma to induce cholesterol
efflux. [22] Our findings are compatible with previous data in
monocytes, where reduced ABCA1 expression was observed in
patients with diabetes and dyslipidaemia.[26]
Our results contrast with studies that showed reduced
expression and function of ABCG1 (but not ABCA1) in monocytes
and macrophages in people with T2DM [27,28], but these earlier
studies were not designed or conducted in drug naive patients who
were free of complications. In the study by Mauldin and colleagues
[28], information pertaining to age, other medical conditions and
drug treatments was unavailable. Forty percent of participants
studied by Zhou et al., had evidence of retinopathy or nephropathy
and all were receiving either oral hypoglycaemic treatments or
insulin treatment.[27] It is feasible that hypoglycaemic treatments
may have contributed to the observed discrepancies in the
relationship between circulating glucose and ABCG1 expression.
For example, insulin decreases human macrophage ABCA1 and
ABCG1 gene expression in vitro.[29] Animal studies indicate that
complications such as nephropathy independently reduce macro-
phage ABCA1 and increase cellular cholesterol content.[30]
Treatment of nephropathy in this study restored ABCA1-
mediated cholesterol efflux in macrophages.[30] The present
study has the advantage of having matched controls and patients
who were drug naive and free of diabetes related complications.
Skin fibroblasts were used to assess ABCA1 function in our
study. Skin fibroblasts have been previously employed for this
purpose, where functional consequences of ABCA1 genetic variants
have been studied.[8] Our tritiated labelled cholesterol-based
technique assessed specific apo-A1-mediated cholesterol efflux
from intracellular and membranous sites to the extracellular
medium. This was derived from a validated methodology.[19]
It should be noted that our gene expression measurements in
leukocytes and cholesterol efflux measurements in fibroblasts were
made against very different backgrounds. Leukocyte gene
expression is likely to relate to conditions under which the leuko-
cytes were taken at the time of sampling, whereas fibroblasts had
undergone prolonged in vitro culture. Despite the prolonged in vitro
conditions at the high glucose levels (25mmol/l) present in the
culture medium, a relationship was apparent between fibroblast
cholesterol efflux and the in vivo glucose concentrations which
pertained at the time of sampling. High medium glucose levels
have not influenced ABCA1 expression in other studies of
leucocytes [31] and the results imply a prolonged metabolic
memory on the part of the cells in humans. Longitudinal studies in
both type I and type 2 diabetes have demonstrated that intensive
glucose lowering leads to fewer cardiovascular disease events many
years later, indicating a possible ‘‘legacy’’ effect.[32,33] The
mechanisms underlying this prolonged benefit are unknown. The
preserved effect of glycaemia, at the time of sampling, on ABCA1
function in fibroblasts in our study may indicate a possible
mechanism.
We have shown that ABCA1-mediated cholesterol efflux is
positively related to plasma HDL-C concentration, compatible
with its key role in HDL formation. This positive relationship
between ABCA1 function and blood HDL-C concentrations has
previously only been described in humans with known ABCA1
mutations.[34] and was not observed in fibroblasts taken from
patients with the metabolic syndrome.[35] It had been thought
that increased intravascular HDL remodelling and catabolism
were the cause of lower HDL-C concentrations in patients with
type 2 diabetes [36] but our observations suggest that reduced
HDL synthesis as a result of impaired ABCA1 function may be a
factor. The positive relationship between LXRa, ABCG1 and
ABCA1 expression testifies to the important role played by LXRa in
the regulation of both ABCA1 and ABCG1 in humans. Although
unsaturated fatty acids negatively regulate ABCA1 expression in
vitro,[12] no relationship was observed with plasma NEFA levels in
our study. PPARc mRNA levels did not significantly relate to
ABCA1 expression in blood leukocytes nor to blood glucose levels.
The latter could be due to altered transcription factor activity or
modification as PPARc phosphorylation has been shown to
influence the glucose lowering effect of the PPARc agonist,
rosiglitazone.[37] ABCG1 has a major role in cholesterol efflux in
humans. However, a human disease caused by ABCG1 dysfunc-
tion has not been identified and ABCG1 deficiency in animal
studies has not consistently shown evidence of increased athero-
sclerosis. This questions whether ABCG1 plays an equally critical
role in preventing atherosclerosis. Unlike ABCA1, ABCG1 does
not have a major role in maintaining plasma HDL-C levels.[38]
Genetic variation in ABCA1 can lead to functional decline. This
is maximal in Tangier disease and observed to a lesser extent in
people with other genetic variants.[39] There have been reports
that some variants may occur more commonly in T2DM com-
pared to the background population.[40,41] It is currently
unknown whether ABCA1 genetic variation leads to altered gene
expression.
It has been proposed that reduced ABCA1 action in humans
leads to impaired b-cell function and reduced insulin secretion has
been reported in some Tangier patients.[42,43] Both ABCA1 and
ABCG1 have been implicated in islet cell function in mice with
ABCG1 shown to have a central role in insulin secretion.[44,45]
PPARc agonists may reduce glucose levels in animals through the
action of ABCA1 in the b-cell.[44] These data suggest that
ABCA1 directly influences glycaemia via its action on b-cell
insulin secretion, but other data suggest that it is glucose which
modifies ABCA1. Recent animal studies have shown decreased
ABCA1 protein and subsequent cellular cholesterol accumula-
tion in macrophages using different mouse models of type I
diabetes.[13] This has been observed in other animal models.[46]
Hyperglycaemia specifically down-regulates ABCA1 and ABCG1
mRNA and protein content in human macrophages in vitro.[21]
Similarly, reduction in gene expression has been reported in
mouse peritoneal macrophages exposed to high glucose concen-
trations.[47] In vascular smooth muscle, hyperglycaemia leads to
reductions in ABCA1 mRNA and protein through changes in
ABCA1 promoter activity, possibly via the p38-mitogen-activated
protein kinase (MAPK) pathway.[48] These studies, along with
our findings in humans, are compatible with a common
glycaemia-mediated suppression of ABCA1. There may, never-
theless be reciprocal interactions between ABCA1 and glycaemia
as decompensation in glucose metabolism progresses and this is an
area requiring future study.
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glycaemia, ABCA1 expression, ABCA1 protein content and
cholesterol removal from cells in humans. Collectively, they
suggest that T2DM is associated with impaired cellular cholesterol
removal via effects on ABCA1 gene expression and function,
impairing the formation of HDL. In humans information
pertaining to RCT is limited. Its importance is highlighted by
recent observation that the cholesterol efflux capacity of plasma in
man has predicted atherosclerosis and coronary disease. [49]
Plasma HDL-C levels accounted for only 40% of the variability in
efflux and other processes in cellular cholesterol removal are likely
to be important.[49] Insights have historically been discovered
from the study of rare genetic disorders of ABCA1, where the
degree of transporter dysfunction related to the severity of pre-
mature atherosclerosis.[34] There has been substantial therapeutic
interest generated by work demonstrating improvements in
atherosclerosis burden in cardiac patients after infusions of human
recombinant Apo-AI (Milano).[50] Moreover, in men with type 2
diabetes, infusion of HDL resulted in short term improvements in
cholesterol removal capacity.[51] Whether augmenting cellular
cholesterol removal will effectively prevent future cardiovascular
events in susceptible patients remains to be proven.
Supporting Information
Figure S1 The relationship of leukocyte ABCG1 expres-
sion to ABCA1 expression and to glycaemia. A. Gene
expression dCt=d cycle number (arbitrary units), rho=0.40,
p=0.005. B. Normalised gene expression versus HbA1c, rho=
20.29, p=0.05.
(TIF)
Figure S2 The relationship of leukocyte Liver X recep-
tor-a (LXRa) gene expression to ABCA1 gene expression
and glycaemia (Hba1c). A. dCt=d cycle number (arbitrary
units), r=0.40, p=0.002. B. Normalised gene expression versus
HbA1c, rho=0.02, p=0.87.
(TIF)
Figure S3 The relationship of leukocyte peroxisome
proliferator-activated receptor-c (PPARc) gene expres-
sion to ABCA1 gene expression and glycaemia. A.
Normalised gene expression, n=23,rho=20.07, p=0.76. B.
Normalised gene expression versus Hba1c, n=23, rho=0.31,
p=0.15.
(TIF)
Acknowledgments
The UK Diabetes Research Network assisted with recruitment and
Imperial College is an NIHR Biomedical Research Centre. We would like
to thank Anna Widdowson from the North West London Diabetes
Research Network, Rosalind Hannen, Julia Feldmeyer and Katarina Leidl
for assistance. Thanks also to Dr Albert Groen and Dr Alan Purohit for
useful advice as well as Christopher Higgins for help in planning the study.
Author Contributions
Conceived and designed the experiments: DCP CA JV DGJ. Performed
the experiments: DCP DP VP CP. Analyzed the data: DCP IFG.
Contributed reagents/materials/analysis tools: CA SPN. Wrote the paper:
DCP CA IFG JV DGJ.
References
1. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, et al. (1985)
Coronary heart disease mortality in relation with diabetes, blood glucose and
plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab
Res Suppl 15: 41–46.
2. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, et al. (2001) Gly-
cated haemoglobin, diabetes, and mortality in men in Norfolk cohort of
European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk).
BMJ 322: 15.
3. Yan SF, Ramasamy R, Naka Y, Schmidt AM (2003) Glycation, Inflammation,
and RAGE: A Scaffold for the Macrovascular Complications of Diabetes and
Beyond. Circ Res 93: 1159–1169.
4. Krentz A (2003) Lipoprotein abnormalities and their consequences for patients
with Type 2 diabetes. Diabetes, obesity & metabolism 5: s19.
5. Yamauchi Y, Chang CC, Hayashi M, be-Dohmae S, Reid PC, et al. (2004)
Intracellular cholesterol mobilization involved in the ABCA1/apolipoprotein-
mediated assembly of high density lipoprotein in fibroblasts. J Lipid Res 45:
1943–1951.
6. Yokoyama S (2005) Assembly of high density lipoprotein by the ABCA1/
apolipoprotein pathway. Curr Opin Lipidol 16: 269–279.
7. Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, et al. (2006) ABCA1 and
ABCG1 Synergize to Mediate Cholesterol Export to ApoA-I. Arterioscler
Thromb Vasc Biol 26: 534–540.
8. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, et al. (1999) The
Tangier disease gene product ABC1 controls the cellular apolipoprotein-
mediated lipid removal pathway. J Clin Invest 104: R25–R31.
9. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, et al. (2002) Increased
Atherosclerosis in Hyperlipidemic Mice With Inactivation of ABCA1 in
Macrophages. Arteriosclerosis, thrombosis, and vascular biology 22: 630–637.
10. Oram J (2000) ABCA1-mediated transport of cellular cholesterol and
phospholipids to HDL apolipoproteins. Current Opinion in Lipidology 11:
253.
11. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, et al. (2001) PPAR-[a]
and PPAR-[c] activators induce cholesterol removal from human macrophage
foam cells through stimulation of the ABCA1 pathway. Nat Med 7: 53–58.
12. Uehara Y, Engel T, Li Z, Goepfert C, Rust S, et al. (2002) Polyunsaturated Fatty
Acids and Acetoacetate Downregulate the Expression of the ATP-Binding
Cassette Transporter A1. Diabetes 51: 2922–2928.
13. Tang C, Kanter JE, Bornfeldt KE, Leboeuf RC, Oram JF (2010) Diabetes
reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys.
J Lipid Res 51: 1719–1728.
14. Passarelli M, Tang C, McDonald TO, O’Brien KD, Gerrity RG, et al. (2005)
Advanced glycation end product precursors impair ABCA1-dependent choles-
terol removal from cells. Diabetes 54: 2198–2205.
15. Albrecht C, Simon-Vermot I, Elliott JI, Higgins CF, Johnston DG, et al. (2004)
Leukocyte ABCA1 gene expression is associated with fasting glucose
concentration in normoglycemic men. Metabolism 53: 17–21.
16. The Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus*. (2003) Follow-up Report on the Diagnosis of Diabetes Mellitus.
Diabetes Care 26: 3160–3167.
17. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, et al. (1985)
Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76–85.
18. Paul V, Meyer HHD, Leidl K, Soumian S, Albrecht C (2008) A novel enzyme
immunoassay specific for ABCA1 protein quantification in human tissues and
cells. Journal of lipid research 49: 2259–2267.
19. de Vries R, Groen AK, Perton FG, linga-Thie GM, van Wijland MJA, et al.
(2008) Increased cholesterol efflux from cultured fibroblasts to plasma from
hypertriglyceridemic type 2 diabetic patients: Roles of pre [b]-HDL,
phospholipid transfer protein and cholesterol esterification. Atherosclerosis
196: 733–741.
20. Albrecht C, Soumian S, Amey JS, Sardini A, Higgins CF, et al. (2004) ABCA1
Expression in Carotid Atherosclerotic Plaques. Stroke 35: 2801–2806.
21. Mauerer R, Ebert S, Langmann T (2009) High glucose, unsaturated and
saturated fatty acids differentially regulate expression of ATP-binding cassette
transporters ABCA1 and ABCG1 in human macrophages. Exp Mol Med 41:
126–132.
22. Hoang A, Tefft C, Duffy SJ, Formosa M, Henstridge DC, et al. (2008) ABCA1
expression in humans is associated with physical activity and alcohol
consumption. Atherosclerosis 197: 197–203.
23. Haghpassand M, Bourassa PA, Francone OL, Aiello RJ (2001) Monocyte/
macrophage expression of ABCA1 has minimal contribution to plasma HDL
levels. J Clin Invest 108: 1315–1320.
24. Zhang Y, McGillicuddy FC, Hinkle CC, O’Neill S, Glick JM, et al. (2010)
Adipocyte Modulation of High-Density Lipoprotein Cholesterol. Circulation
121: 1347–1355.
25. van EM, Bos IS, Kaminski WE, Orso E, Rothe G, et al. (2002) Leukocyte
ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment
into tissues. Proc Natl Acad Sci U S A 99: 6298–6303.
26. Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M (2002) Mechanisms
of the Triglyceride- and Cholesterol-Lowering Effect of Fenofibrate in
Hyperlipidemic Type 2 Diabetic Patients. Diabetes 51: 3486–3491.
Expression and Function of ABCA1 in Diabetes
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e2214227. Zhou H, Tan KCB, Shiu SWM, Wong Y (2008) Determinants of leukocyte
adenosine triphosphate-binding cassette transporter G1 gene expression in type
2 diabetes mellitus. Metabolism 57: 1135–1140.
28. Mauldin JP, Nagelin MH, Wojcik AJ, Srinivasan S, Skaflen MD, et al. (2008)
Reduced Expression of ATP-Binding Cassette Transporter G1 Increases
Cholesterol Accumulation in Macrophages of Patients With Type 2 Diabetes
Mellitus. Circulation 117: 2785–2792.
29. Sporstol M, Mousavi SA, Eskild W, Roos N, Berg T (2007) ABCA1, ABCG1
and SR-BI: hormonal regulation in primary rat hepatocytes and human cell
lines. BMC Mol Biol 8: 5.
30. Zuo Y, Yancey P, Castro I, Khan W, Motojima M, et al. (2009) Renal
Dysfunction Potentiates Foam Cell Formation by Repressing ABCA1.
Arterioscler Thromb Vasc Biol 29: 1277–1282.
31. Senanayake S, Brownrigg LM, Panicker V, Croft KD, Joyce DA, et al. (2007)
Monocyte-derived macrophages from men and women with Type 2 diabetes
mellitus differ in fatty acid composition compared with non-diabetic controls.
Diabetes Research and Clinical Practice 75: 292–300.
32. The Diabetes Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications (DCCT/EDIC) Study Research Group (2005)
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type
1 Diabetes 7. N Engl J Med 353: 2643–2653.
33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-Year
Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 359:
1577–1589.
34. van Dam MJ, de GE, Clee SM, Hovingh GK, Roelants R, et al. (2002)
Association between increased arterial-wall thickness and impairment in
ABCA1-driven cholesterol efflux: an observational study. Lancet 359: 37–42.
35. Alenezi MY, Marcil M, Blank D, Sherman M, Genest J Jr. (2004) Is the
decreased high-density lipoprotein cholesterol in the metabolic syndrome due to
cellular lipid efflux defect? J Clin Endocrinol Metab 89: 761–764.
36. Frenais R, Ouguerram K, Maugeais C, Mahot P, Maugere P, et al. (1997) High
density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study.
Diabetologia 40: 578–583.
37. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, et al. (2010) Anti-diabetic
drugs inhibit obesity-linked phosphorylation of PPAR[g] by Cdk5. Nature 466:
451–456.
38. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, et al. (2005)
ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing
cellular lipid accumulation. Cell Metab 1: 121–131.
39. Singaraja RR, Visscher H, James ER, Chroni A, Coutinho JM, et al. (2006)
Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid
phenotypes both in vivo and in vitro. Circ Res 99: 389–397.
40. Daimon M, Kido T, Baba M, Oizumi T, Jimbu Y, et al. (2005) Association of
the ABCA1 gene polymorphisms with type 2 DM in a Japanese population.
Biochem Biophys Res Commun 329: 205–210.
41. Villarreal-Molina MT, Flores-Dorantes MT, Rellano-Campos O, Villalobos-
Comparan M, Rodriguez-Cruz M, et al. (2008) Association of the ATP-Binding
Cassette Transporter A1 R230C Variant With Early-Onset Type 2 Diabetes in a
Mexican Population. Diabetes 57: 509–513.
42. Vergeer M, Brunham LR, Koetsveld J, Kruit JK, Verchere CB, et al. (2010)
Carriers of Loss-of-Function Mutations in ABCA1 Display Pancreatic B Cell
Dysfunction. Diabetes Care.
43. Koseki M, Matsuyama A, Nakatani K, Inagaki M, Nakaoka H, et al. (2009)
Impaired insulin secretion in four Tangier disease patients with ABCA1
mutations. J Atheroscler Thromb 16: 292–296.
44. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, et al. (2007) B-
cell ABCA1 influences insulin secretion, glucose homeostasis and response to
thiazolidinedione treatment. Nat Med 13: 340–347.
45. Sturek JM, Castle JD, Trace AP, Page LC, Castle AM, et al. (2010) An
intracellular role for ABCG1-mediated cholesterol transport in the regulated
secretory pathway of mouse pancreatic +| cells. The journal of clinical
investigation 120: 2575–2589.
46. Zhu Y, Wang HJ, Chen LF, Fang Q, Yan XW (2007) Study of ATP-binding
cassette transporter A1 (ABCA1)-mediated cellular cholesterol efflux in diabetic
golden hamsters. J Int Med Res 35: 508–516.
47. Gao F, Yan T, Zhao Y, Yin F, Hu C (2010) A possible mechanism linking
hyperglycemia and reduced high-density lipoprotein cholesterol levels in
diabetes. J Huazhong Univ Sci Technolog Med Sci 30: 318–321.
48. Yu X, Murao K, Imachi H, Li J, Nishiuchi T, et al. (2010) Hyperglycemia
suppresses ABCA1 expression in vascular smooth muscle cells. Horm Metab Res
42: 241–246.
49. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, et al.
(2011) Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and
Atherosclerosis. New England Journal of Medicine 364: 127–135.
50. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, et al. (2003)
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients
with acute coronary syndromes: a randomized controlled trial. JAMA 290:
2292–2300.
51. Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, et al. (2009) Reconstituted
high-density lipoprotein increases plasma high-density lipoprotein anti-inflam-
matory properties and cholesterol efflux capacity in patients with type 2 diabetes.
J Am Coll Cardiol 53: 962–971.
Expression and Function of ABCA1 in Diabetes
PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22142